Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Diabetic Peripheral Neuropathy
Interventions
DRUG

Pregabalin 150mg + Alpha-lipoic acid 480mg

Pregabalin qd + alpha-lipoic acid qd

DRUG

Pregabalin 150mg

pregabalin qd

DRUG

Alpha-Lipoic Acid 480mg

alpha-lipoic acid qd

Trial Locations (14)

Unknown

Pusan National University Hospital, Busan

Chosun University Hospital, School of Medicine, Chosun University, Gwangju

Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggi-do

Seoul National University Bundang Hospital, Gyeonggi-do

The Catholic University of Korea, Incheon ST. Mary's Hospital, Incheon

Jeju National University College of Medicine, Jeju City

Jeonbuk National University Hospital, Jeollabuk-do

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Inje University Sanggye Paik Hospital, Seoul

Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul

Korea University Guro Hospital, Seoul

Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul

Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul

Ulsan University Hospital, College of Medicine University of Ulsan, Ulsan

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY